Lantheus (NASDAQ:LNTH) Issues FY 2025 Earnings Guidance

Lantheus (NASDAQ:LNTH) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 7.000-7.200 for the period, compared to the consensus estimate of 6.980. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. JMP Securities reiterated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. The Goldman Sachs Group initiated coverage on shares of Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. Finally, Truist Financial lifted their price objective on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $132.86.

Lantheus Stock Down 0.4 %

Shares of NASDAQ:LNTH opened at $91.13 on Friday. The company has a 50 day moving average of $89.80 and a two-hundred day moving average of $96.75. Lantheus has a 52-week low of $56.44 and a 52-week high of $126.89. The company has a market capitalization of $6.34 billion, a price-to-earnings ratio of 15.34 and a beta of 0.44.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). The business had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. On average, equities analysts anticipate that Lantheus will post 6.01 earnings per share for the current year.

Insider Transactions at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.